Middle East and Africa Lung Transplant Therapeutics Market, By Product (Immunosuppressant Drugs, Organ Preservation Products, Tissue Products, and Others), Indication (Chronic Obstructive Pulmonary Diseases (COPD), Pulmonary Fibrosis, Septic Lung Disease, Pulmonary Hypertension, Cystic Fibrosis, Interstitial Pulmonary Fibrosis, Emphysema, Sarcoidosis, Primary Pulmonary Arterial Hypertension, and Others), Type (Cadaveric Lung Transplantation, Living Lung Transplantation), Technique (Single-Lung Transplantation, Bilateral-Lung Transplantation, Heart-Lung Transplantation, and Double Lung Transplantation), Patient Demographics (Geriatric, Adult, Paediatric), End Users (Hospital, Transplant Centres, Specialty Centres, and Others), Country (Saudi Arabia, South Africa, Israel, U.A.E., Rest of the Middle East and Africa) Industry Trends and Forecast to 2029
Market Analysis and Insights : Middle East and Africa Lung Transplant Therapeutics Market
Middle-East and Africa lung transplant therapeutics market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 2.5% in the forecast period of 2022 to 2029 and is expected to reach USD 2.78 million by 2029. Increase in new innovative treatment for surgeries and therapies and rise in respiratory chronic diseases due to rise in pollution are the major drivers that may propel the demand of the market in the forecast period.
A lung transplant is a surgical procedure done to remove an unhealthy lung and replace it with a healthy lung from another person. Unhealthy or damaged lungs can make it difficult for a patient body to get the oxygen it needs to survive the day to day need of body functions like respiration which help in balancing pH in the body by increasing the ventilation rate whenever the acidity rise due to carbon dioxide accumulation to expel more of unwanted gas which helps in balancing pH. A variety of diseases like asthma, inflammation in bronchial tubes and lungs, and the buildup of fluid in lungs, and lung cancer and conditions can damage the lungs and hamper their ability to function effectively.
Increasing drug approvals, rise in clinical trials, high incidence of chronic disease, and ongoing research to increase the therapeutics application is expected to drive the market's growth. However, fewer donors for organ donation and the high cost of lung transplant procedures may hamper the market growth. Meanwhile, rising healthcare spending, strategic initiatives by market players, technological advancements in lung transplantation may create opportunities for market growth. Stringent regulatory framework and complications associated with lung transplantation may challenge the market growth.
The Middle East and Africa lung transplant therapeutics market report provide details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief; our team will help you create a revenue impact solution to achieve your desired goal.
Middle East and Africa Lung Transplant Therapeutics Market Scope and Market Size
The Middle East and Africa lung transplant therapeutics market is segmented into product, type, indication, technique, patient demographics, and end users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of product, the Middle East and Africa lung transplant therapeutics market is segmented into immunosuppressant drugs, tissue products, organ preservation products, and others. In 2022, the immunosuppressant drugs segment is expected to dominate the Middle East and Africa lung transplant therapeutics market due to the increase in the effectiveness of immune system suppressant drugs in patients to avoid lung rejection.
- On the basis of type, the Middle East and Africa lung transplant therapeutics market is segmented into cadaveric lung transplantation and living lung transplantation. In 2022, the cadaveric lung transplantation segment is expected to dominate the Middle East and Africa lung transplant therapeutics market due to increased organ donation and its applications.
- On the basis of indication, the Middle East and Africa lung transplant therapeutics market is segmented into chronic obstructive pulmonary diseases (COPD), pulmonary fibrosis, septic lung disease, pulmonary hypertension, cystic fibrosis, interstitial pulmonary fibrosis, emphysema, primary pulmonary arterial hypertension sarcoidosis, and others. In 2022, the cystic fibrosis segment is expected to dominate the Middle East and Africa lung transplant therapeutics market due to the increase in the vulnerable older patient population of cystic fibrosis patients in region.
- On the basis of technique, the Middle East and Africa lung transplant therapeutics market is segmented into single-lung transplantation, bilateral-lung transplantation, heart-lung transplantation, and double lung transplantation. In 2022, the single-lung transplantation (SLT) segment is expected to dominate the Middle East and Africa lung transplant therapeutics market due to the surge in advanced lung transplantation procedures.
- On the basis of patient demographics, the Middle East and Africa lung transplant therapeutics market is segmented into adult, pediatric, and geriatric. In 2022, the adult segment is expected to dominate the Middle East and Africa lung transplant therapeutics market due to the increase in adult population.
- On the basis of end users, the Middle East and Africa lung transplant therapeutics market is segmented into hospital, transplant centers, specialty centers, and others. In 2022, the hospital segment is expected to dominate the Middle East and Africa lung transplant therapeutics market due to hospitals as the primary point of healthcare and effective place for the surgeries with skilled doctors and increased awareness regarding organ donation, registration, and chronic diseases.
Middle East and Africa Lung Transplant Therapeutics Market Country Level Analysis
The Middle East and Africa lung transplant therapeutics market is analyzed, and market size information is provided based on product, type, indication, technique, patient demographics, and end users.
Some of the countries covered in the Middle East and Africa lung transplant therapeutics market are Saudi Arabia, South Africa, U.A.E., Israel, Egypt and Rest of Middle East and Africa.
The immunosuppressant drugs segment in the Middle East and African region is expected to grow with the highest growth rate in the forecast period of 2022 to 2029 because of increasing clinical trials and research development for the prevention of chronic diseases. Saudi Arabia is expected to lead the growth of the Middle East and Africa market due to increasing lung transplant surgeries every year results in larger approval of drugs for transplant. South Africa is expected to dominate with a continuous increase in investments for research and development.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of the Middle East and African brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
Rise in Healthcare Expenditure and Chronic Diseases boost the Middle East and Africa Lung Transplant Therapeutics Market Growth
The Middle East and Africa lung transplant therapeutics market also provide you with detailed market analysis for every country's growth in the lung transplant industry with sales, impact of advancement in the lung transplant technology, and changes in regulatory scenarios with their support for the lung transplant therapeutics market. The data is available for historic period 2011 to 2020.
Competitive Landscape and Middle East and Africa Lung Transplant Therapeutics Market Share Analysis
The Middle East and Africa lung transplant therapeutics market competitive landscape provide details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points are only related to the company's focus on the Middle East and Africa lung transplant therapeutics market.
Some major manufacturers for the Middle East and Africa lung transplant therapeutics market are Bridge to Life Ltd, Viatris Inc., BioLife Solutions, Pfizer Inc., F.Hoffmann-La Roche Ltd., Panacea Biotec Ltd., Accord-UK Ltd, Novartis AG, Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories Ltd., among others.
Various market players provides better healthcare services which are also accelerating the Middle East and Africa lung transplant therapeutics market
For instance,
- In January 2022, Hikma Pharmaceuticals PLC expanded in Canada with Teligent sterile injectable, including a portfolio of 25 sterile injectable products, three in-licensed ophthalmic products, and a pipeline of seven additional products, four of which are approved by Health Canada. This portfolio of exciting products will enable the company to expand North American business and develop a solid position in this important market
Collaboration, product launch, business expansion, award and recognition, joint ventures, and other market players enhance the company in the Middle East and Africa lung transplant therapeutics market, which also benefits the organization to improve its offering.
SKU-